Optimizing Cotreatment of HCV and HIV Infection

This comprehensive program on managing HCV/HIV coinfection features an Interactive Decision Support Tool to compare your treatment choices with guideline recommendations, an educational module with accompanying downloadable slideset for fast and efficient learning, and more.
Annie Luetkemeyer Headshot
Annie Luetkemeyer, MD
Susanna Naggie, MD, MHS
Mark S. Sulkowski, MD


All PLWH who are coinfected with HCV should be offered curative HCV treatment. Nonadherence to ART or a lack of HIV suppression should not affect candidacy for treatment of HCV.

Mark S. Sulkowski, MD Released: November 8, 2018

Managing people living with both HIV and HCV and polypharmacy can be difficult. How do you analyze which HCV regimen to use and identify relevant drug interactions?

Annie Luetkemeyer Headshot Annie Luetkemeyer, MD Released: December 12, 2018

Treatment of HCV/HIV coinfection requires continued awareness of and attention to the complex drug–drug interactions that can occur, especially when using pharmacologically boosted ARVs and nonnucleoside reverse transcriptase inhibitors. Here’s my take on how to approach drug–drug interactions using patient cases.

Susanna Naggie, MD, MHS Released: January 25, 2019
Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
PIM Logo

Postgraduate Institute for Medicine
304 Inverness Way South, Suite 100
Englewood, CO 80112

Allison Hughes, CCMEP, Program Manager
(303) 799-1930
(303) 858-8842 (Fax)

Supported by an independent educational grant from
Gilead Sciences

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.